COGNITION THERAPEUTICS INC (CGTX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.06

From 52W high−46.67%

Volume336186.00

Market cap$98.90M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.06

From 52W high

−46.67%

Volume

336186.00

Market cap

$98.90M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.9x

P/E (TTM)

—

RSI (14)

56.3

MomentumView details →

1D Return

−1.89%

YTD Return

−21.50%

SummaryUpdated Jun 1, 2026

Cognition Therapeutics, Inc. (NASDAQ:CGTX) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Purchase, New York. The company went public in October 2021 and focuses on developing small molecule therapeutics for age-related degenerative diseases affecting the central nervous system and retina. Cognition Therapeutics is currently advancing multiple clinical trials for its lead drug candidate across several neurodegenerative conditions, with significant backing from National Institutes of Health grants totaling over $170 million in non-dilutive funding.

Ask drillr about COGNITION THERAPEUTICS INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.9x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

3.0x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−50.80%

ROA (TTM)

−43.13%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+71.34%

FCF YoY

+42.40%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+62.35%

EBITDA YoY

+49.37%

MomentumView details →

1D Return

−1.89%

YTD Return

−21.50%

1Y Return

−24.31%

RSI (14)

56.3

vs 50D SMA

+5.88%

vs 200D SMA

−9.43%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

7.03x

Quick Ratio

7.03x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.04

EPS Surprise

36.84%

Beats (12Q)

9/12

Next Q EPS Est

−$0.07

Avg Surprise (4Q)

33.61%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−16.77M

Op. CF (TTM)

−17.68M

Next earningsNov 5, 2026 →

Latest newsMore news →

Cognition Therapeutics, Inc. reported a second-quarter loss of $0.04 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and the year-ago loss of $0.11 per share.45d ago

Cognition Therapeutics received written feedback from the FDA agreeing that psychosis associated with dementia with Lewy bodies could be an approvable outcome and aligning on key aspects of a pivotal trial for Zervimesine (CT1812).88d ago

Similar companies

Nutriband Inc.NTRB Rani Therapeutics Holdings, Inc.RANI Oncolytics Biotech Inc.ONCY Atara Biotherapeutics, Inc.ATRA Anixa Biosciences, Inc.ANIX Polaryx Therapeutics, Inc. Common StockPLYX Find similar companies →

Latest newsMore news →

Cognition Therapeutics, Inc. reported a second-quarter loss of $0.04 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and the year-ago loss of $0.11 per share.45d ago Cognition Therapeutics received written feedback from the FDA agreeing that psychosis associated with dementia with Lewy bodies could be an approvable outcome and aligning on key aspects of a pivotal trial for Zervimesine (CT1812).88d ago